TRIM27 Antibody

• 产品编号：CST-12663S      品牌：Cell Signaling Technology       原厂货号：12663S
• 产品分类：抗体 > 一抗 > 蛋白特异性一抗
• 应用分类：

描述：

TRIM27 抗体识别内源性的TRIM27总蛋白。在一些细胞系中130 kDa可以检测到背景带。该多克隆抗体经合成与人 TRIM27蛋白Leu255邻近氨基酸残基序列一致的肽段，免疫动物产生。该抗体由蛋白A和肽亲和层析纯化。含有三分模序的蛋白27(TRIM27, RFP) 是含有三分模序的(TRIM)蛋白家族成员之一，该家族含有一个环结构域、一个B-box、一个卷曲螺旋区域（总称为RBCC）。TRIM27最初被认为是致癌性DNA重组的部分，可以导致TRIM27氨基末端的RBCC区域与受体酪氨酸激酶Ret的羧基末端激酶区域的融合（1）。TRIM27会诱使JNK和凋亡中p38 MAPK的活化 (2)。TRIM27具有多效性，包括抑制转录(3,4)，泛素E3连接酶活性(5-7)，以及SUMO化(8)。最初发现TRIM27与Enhancer of Polycomb (EPC)存在相互作用中发现，其作为转录抑制因子(3)。后续的研究表明TRIM27以及其它TRIM家族的成员具有泛素E3连接酶活性(见参考文献 9)。TRIM27可能的底物介导泛素化作用，包括class II PI3K-C2β, NOD2, 和WASH。在几种癌症中发现TRIM27表达增强，在一些情况下，它可能意味着愈后不良(10-13)。

1. Takahashi, M. et al. (1988) Mol Cell Biol 8, 1853-6.
2. Dho, S.H. and Kwon, K.S. (2003) J Biol Chem 278, 31902-8.
3. Shimono, Y. et al. (2000) J Biol Chem 275, 39411-9.
4. Bloor, A.J. et al. (2005) Oncogene 24, 6729-36.
5. Cai, X. et al. (2011) Proc Natl Acad Sci U S A 108, 20072-7.
6. Zurek, B. et al. (2012) PLoS One 7, e41255.
7. Hao, Y.H. et al. (2013) Cell 152, 1051-64.
8. Chu, Y. and Yang, X. (2011) Oncogene 30, 1108-16.
9. Meroni, G. and Diez-Roux, G. (2005) Bioessays 27, 1147-57.
10. Tezel, G.G. et al. (2009) Pathol Res Pract 205, 403-8.
11. Tsukamoto, H. et al. (2009) Cancer Sci 100, 1895-901.
12. Iwakoshi, A. et al. (2012) Pathol Int 62, 324-30.
13. Zoumpoulidou, G. et al. (2012) J Natl Cancer Inst 104, 941-52.

原厂资料：

Homology

Species predicted to react based on 100% sequence homology: Monkey, Bovine

Specificity / Sensitivity

TRIM27 Antibody recognizes endogenous levels of total TRIM27 protein. A background band is detected in some cell lines at 130 kDa.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu255 of human TRIM27 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

Tripartite motif containing protein 27 (TRIM27, RFP) is a member of the tripartite motif (TRIM) family whose members contain a RING domain, a B-box, and a coiled-coil region (together called RBCC). TRIM27 was originally discovered as part of an oncogenic DNA rearrangement resulting in fusion of the amino terminal RBCC region of TRIM27 with the carboxyl terminal kinase domain of the receptor tyrosine kinase Ret (1). Overexpression of TRIM27 induces JNK and p38 MAPK activation as well as apoptosis (2). TRIM27 has been found to have pleiotropic effects including transcriptional repression (3,4), and E3 ligase activity for ubiquitin (5-7), and SUMO (8). TRIM27 was originally found to interact with Enhancer of Polycomb (EPC) and function as a transcriptional repressor (3). Subsequent studies have identified ubiquitin E3 ligase activity in TRIM27 as well as other members of the TRIM family (reviewed in 9). Potential substrates of TRIM27 mediated ubiquitination include class II PI3K-C2β, NOD2, and WASH. Elevated expression of TRIM27 has been observed in several cancer types of cancer, where in some cases it may be a predictor of poor prognosis (10-13).

1. Takahashi, M. et al. (1988) Mol Cell Biol 8, 1853-6.
2. Dho, S.H. and Kwon, K.S. (2003) J Biol Chem 278, 31902-8.
3. Shimono, Y. et al. (2000) J Biol Chem 275, 39411-9.
4. Bloor, A.J. et al. (2005) Oncogene 24, 6729-36.
5. Cai, X. et al. (2011) Proc Natl Acad Sci U S A 108, 20072-7.
6. Zurek, B. et al. (2012) PLoS One 7, e41255.
7. Hao, Y.H. et al. (2013) Cell 152, 1051-64.
8. Chu, Y. and Yang, X. (2011) Oncogene 30, 1108-16.
9. Meroni, G. and Diez-Roux, G. (2005) Bioessays 27, 1147-57.
10. Tezel, G.G. et al. (2009) Pathol Res Pract 205, 403-8.
11. Tsukamoto, H. et al. (2009) Cancer Sci 100, 1895-901.
12. Iwakoshi, A. et al. (2012) Pathol Int 62, 324-30.
13. Zoumpoulidou, G. et al. (2012) J Natl Cancer Inst 104, 941-52.

注意事项：

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.
*Species cross-reactivity is determined by western blot.
** Anti-rabbit secondary antibodies must be used to detect this antibody.